Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
出版年份 2020 全文链接
标题
Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
作者
关键词
-
出版物
Cancers
Volume 12, Issue 4, Pages 804
出版商
MDPI AG
发表日期
2020-04-01
DOI
10.3390/cancers12040804
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Hyperprogression upon immunotherapy: A chance for (hyper-)progress
- (2020) Roch Houot et al. EUROPEAN JOURNAL OF CANCER
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function
- (2019) Catherine Konopacki et al. NATURE IMMUNOLOGY
- Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist
- (2019) G.R. Ferretti et al. Diagnostic and Interventional Imaging
- The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination
- (2019) Kenichi Suda Journal of Thoracic Disease
- PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!
- (2019) Paul Hofman Journal of Thoracic Disease
- Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment
- (2019) Concetta Elisa Onesti et al. Journal of Thoracic Disease
- Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
- (2019) Ilke Tunali et al. LUNG CANCER
- Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties
- (2019) Roland G Stein et al. CANCER RESEARCH
- Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
- (2019) Yada Kanjanapan et al. CANCER
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
- (2019) C G Kim et al. ANNALS OF ONCOLOGY
- Hyperprogression under Immunotherapy
- (2019) Frelaut et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploring the emerging role of the microbiome in cancer immunotherapy
- (2019) Jessica Fessler et al. Journal for ImmunoTherapy of Cancer
- Hyperprogression during immunotherapy: do we really want to know?
- (2019) S Champiat et al. ANNALS OF ONCOLOGY
- The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
- (2019) Erich Sabio et al. Genome Medicine
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
- (2019) Erick Riquelme et al. CELL
- Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
- (2019) Christophe Dumet et al. mAbs
- Hyperprogressive disease with immunotherapy: new directions
- (2019) Sally C. M. Lau et al. Journal of Thoracic Disease
- Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
- (2019) Daniel A. Rauch et al. BLOOD
- Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
- (2019) Komugi Okeya et al. INTERNAL MEDICINE
- Gut microbiome and cancer immunotherapy
- (2019) Jin‐Yu Sun et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming
- (2019) Edina Gyukity-Sebestyén et al. Frontiers in Immunology
- Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?
- (2019) R. Califano et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab Interferes with the Differentiation of Human FOXP3+–Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR
- (2019) Varun Sasidharan Nair et al. JOURNAL OF IMMUNOLOGY
- Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer
- (2019) Stergios Doumas et al. ORAL ONCOLOGY
- Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
- (2019) Guillaume Manson et al. Journal for ImmunoTherapy of Cancer
- Structure and Optimization of Checkpoint Inhibitors
- (2019) Sarah L. Picardo et al. Cancers
- PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
- (2018) Xin Yao Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hyperprogression as a Distinct Outcome after Immunotherapy
- (2018) J. Fuentes-Antrás et al. CANCER TREATMENT REVIEWS
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
- (2018) Jonathan S. Kurman et al. Journal of Thoracic Disease
- Do immune checkpoint inhibitors need new studies methodology?
- (2018) Roberto Ferrara et al. Journal of Thoracic Disease
- Immunotherapy in the Asiatic population: any differences from Caucasian population?
- (2018) Lunxi Peng et al. Journal of Thoracic Disease
- Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
- (2018) Shisuo Du et al. OncoImmunology
- Abstract LB-115: Tumor intrinsic PD-1/PD-L1 signalling induces mesenchymal to epithelial transition in canine osteosarcoma cells
- (2018) Maciej Parys et al. CANCER RESEARCH
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
- (2018) Han Yao et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- 1211PHyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?
- (2018) E Farè et al. ANNALS OF ONCOLOGY
- 54PDPre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression
- (2018) M Zuazo et al. ANNALS OF ONCOLOGY
- Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism
- (2018) David A. Knorr et al. CLINICAL CANCER RESEARCH
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells
- (2018) Sayantani Ghosh et al. Nature Communications
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice
- (2017) Vassil Dimitrov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- PD-1 and PD-L1 expression in bone and soft tissue sarcomas
- (2017) Alireza Torabi et al. PATHOLOGY
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
- (2017) Veronica Huber et al. SEMINARS IN CANCER BIOLOGY
- Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
- (2017) Yunfei Liao et al. Oncotarget
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
- (2016) M. F. Sanmamed et al. ANNALS OF ONCOLOGY
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing
- (2016) Judith Balmaña et al. JOURNAL OF CLINICAL ONCOLOGY
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
- (2015) Shari Pilon-Thomas et al. CANCER RESEARCH
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- How Drugs are Developed and Approved by the FDA: Current Process and Future Directions
- (2014) Arthur A Ciociola et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
- (2014) Vassiliki A. Boussiotis et al. CANCER JOURNAL
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display
- (2014) Christian Schröter et al. mAbs
- The cellular and molecular origin of tumor-associated macrophages
- (2014) R. A. Franklin et al. SCIENCE
- Impact of aging in cancer immunotherapy
- (2014) Myriam N Bouchlaka et al. OncoImmunology
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic responses in mouse models poorly mimic human inflammatory diseases
- (2013) Junhee Seok et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cohabiting family members share microbiota with one another and with their dogs
- (2013) Se Jin Song et al. eLife
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia
- (2011) S. Zhou et al. MOLECULAR AND CELLULAR BIOLOGY
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis
- (2010) Iglika K. Djoumerska-Alexieva et al. FEBS Journal
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
- (2009) Melissa Paoloni et al. BMC GENOMICS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Mouse xenograft models vs GEM models for human cancer therapeutics
- (2008) A. Richmond et al. Disease Models & Mechanisms
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation